Tomi Jun, MD, Stanford University School of Medicine, discusses the results of a study of cirrhosis and long-term survival in patients with cryptogenic hepatocellular carcinoma (HCC).

This was a multi-center, international cohort of about 4000 patients out of the United States and Taiwan that aimed to evaluate the significantly lower rates of cirrhosis and worse long-term survival in patients with cryptogenic HCC compared with viral etiologies.

Although patients with cryptogenic HCC showed less cirrhosis, survival was significantly lower than what was shown in patients with hepatitis b- and hepatitis c-related HCC.

View more from the 2017 International Liver Congress

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Gastrointestinal Cancer

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

International Liver Congress

Tomi Jun, MD, Stanford University School of Medicine, discusses the results of a study of cirrhosis and long-term survival in patients with cryptogenic hepatocellular carcinoma. 

Dr. Jun on Results of Study in Cryptogenic Hepatocellular Carcinoma